Volume 31, No 3, Mar 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 3, March 2021: 243-244   |  Open Access

RESEARCH HIGHLIGHTS

Dalbavancin: novel candidate for COVID-19 treatment

Markus Hoffmann^1,2,* , Yeonhwa Jin^1,2 , Stefan Pöhlmann^1,2,*

¹Infection Biology Unit, German Primate Center, 37077 Göttingen, Germany
²Faculty of Biology and Psychology, Georg-August-University Göttingen, 37073 Göttingen, Germany
Correspondence: Markus Hoffmann(mhoffmann@dpz.eu)Stefan Pöhlmann(spoehlmann@dpz.eu)

Antivirals approved for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the associated coronavirus disease 2019 (COVID-19) are largely lacking. In a recent study in Cell Research, Wang et al. show that the clinically proven antibiotic dalbavancin blocks SARS-CoV-2 binding to its receptor ACE2 and reduces viral spread and pathogenesis in animal models.

https://doi.org/10.1038/s41422-020-00459-5

FULL TEXT | PDF

Browse 617